Associated Papers
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
38564707 (PubMed )
Supplement: cd-23-1217_supplementary_table_2_suppst2.pdf
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
Spitaleri G et al.
Cancers, 2023
The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.
Albers J et al.
Molecular Cancer Therapeutics, 2023
Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients.
Wong SQ et al.
British Journal of Cancer, 2015
25742471 (PubMed )
Supplement: bjc201580x7.xls › Supp_Table_3
Select a paper to view details